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Transformation and clonal proliferation of T-cells infected with human T-cell leukemia virus type-I (HTLV-1) cause
adult T-cell leukemia. We took advantage of next-generation sequencing technology to develop and internally
validate a new methodology for isolating integration sites and estimating the number of cells in each HTLV-1-infected
clone (clone size). Initial analysis was performed with DNA samples from infected individuals. We then used appropriate
controls with known integration sites and clonality status to confirm the accuracy of our system, which indeed had the
least errors among the currently available techniques. Results suggest potential clinical and biological applications of
the new method.Background
It has been more than 30 years since human T-cell
leukemia virus type-I (HTLV-1) was shown to be the
causative agent of adult T-cell leukemia (ATL) [1,2].
However, understanding the true nature of the multiple
leukemogenic events [3] that are essential for this ag-
gressive transformation remains elusive [4-9]. Although
approximately 5% of HTLV-1-infected individuals de-
velop ATL after a long latency period, the majority re-
main asymptomatic carriers (ACs) throughout their
lifetimes. However, there are not enough clear determi-
nants to distinguish between individuals who eventually
develop ATL and those who remain as ACs [10,11]. To
discover the factors associated with disease development,
long-term prospective studies have assessed the correl-
ation between disease outcome and proviral load (PVL),
that is, the percentage of infected cells among the total
peripheral blood mononuclear cells (PBMCs) [10-12]. The
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unless otherwise stated.(JSPFAD) [13] showed that a PVL higher than 4% is
one of the indications of risk for progression to ATL
[10]. Although an elevated PVL is currently the best
characterized factor associated with a high risk of ATL
development, a high PVL alone is not sufficient for
disease prediction, suggesting the need to discover
additional predictive factors [10,11].
Because ATL is a malignancy caused by HTLV-1 infec-
tion, both the integration of provirus into the host genome
and the clonal expansion of infected cells are highly critical
leukemogenic events [6,7,14,15]. Although many studies
have addressed these aspects, the mechanism of HTLV-1
clonal expansion has not been elucidated [15-35]. Accurate
monitoring for changes in clonality occurring before, dur-
ing, and after ATL development is of great interest and of
major clinical significance not only to clarify the underlying
mechanisms but also to discover reliable predictive bio-
markers for disease progression.
A broad range of evidence strongly supports that most
neoplasms are composed of clonally expanded cell popula-
tions [36-38]. Owing to its biological significance, the
concept of clonal expansion in cancer biology has been in-
vestigated using a variety of approaches in many tumor
types [36-39], including ATL [6,15,16,18-20,22,24,29-32].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tected as monoclonal-derived bands by southern blotting
[33]. Early studies found that monoclonal integration of
HTLV-1 is a hallmark of ATL cells [16]. Furthermore, it
was suggested that detecting a monoclonal band is useful
for diagnosis and is associated with a high risk of ATL
development [29,30]. Subsequent PCR-based methods
included inverse PCR, linker-mediated PCR, and inverse
long PCR, which enabled analysis of samples with
clonality below the detection threshold of southern
blotting [17,25,31,34]. Based on the observed banding
patterns, the clonality of the samples was described as
having undergone monoclonal, oligoclonal, or poly-
clonal expansion. Such PCR-based analyses revealed
that, in addition to a monoclonal proliferation of in-
fected cells, a monoclonal or polyclonal proliferation
occurs even in non-malignant HTLV-1 carriers [31,35].
Moreover, considering the stability of the HTLV-1 pro-
viral sequence, it was hypothesized that maintaining a
high PVL is achieved by persistent clonal proliferation
of infected cells in vivo [25]. This hypothesis was fur-
ther supported by the detection of a particular HTLV-1
clone in the same carrier over the course of several
years [18]. Two Miyazaki cohort studies focused on the
maintenance and establishment of clonal expansion:
Okayama et al. analyzed the maintenance of a pre-
leukemic clone in an AC state several years prior to
ATL onset [19], and Tanaka et al. assessed the establish-
ment of clonal expansion by comparing the clonality status
of long-term carriers with that of seroconverters. They
showed that some of the clones from long-term carriers
were stable and large enough to be consistently detectable
by inverse long PCR; however, those from seroconverters
were unstable and rarely detectable over time [20].
Knowledge provided by conventional studies has
shed light on the next challenges worthy of further in-
vestigation. Owing to technical hurdles, however, previous
studies isolated small numbers of integration sites from
highly abundant clones and detected low abundant clones
in a non-reproducible manner [22,34]. Furthermore, con-
ventional techniques could not provide adequate informa-
tion regarding the number of infected cells in each clone
(clone size) [22]. To effectively track and monitor HTLV-1
clonal composition and dynamics, we considered devising
a new method that would not only enable the high-
throughput isolation of integration sites but also provide an
accurate measurement of clone size.
PCR is a necessary step for the integration site isolation
and clonality analysis. However, bias in the amplification of
DNA fragments (owing to issues such as extreme fragment
length and high GC content) is intrinsic to any PCR-based
method [40-45]. Different fragment amplification efficien-
cies make it difficult to calculate the amount of starting
DNA (the original distribution of template DNA) fromPCR products. Hence, estimating HTLV-1 clonal abun-
dance, which requires calculating the number of start-
ing DNA fragments, is only achievable by avoiding the
PCR bias.
Recently, Bangham’s research group analyzed HTLV-1
clonality and integration site preference by a high-
throughput method [22]. In the method developed by
Gillet et al., clone sizes were estimated using length of
DNA fragments (shear sites generated by sonication) as
a strategy for removing PCR bias [22]. Owing to the
limited variation in DNA fragment size observed with
shearing, the probability of generating starting fragments
of the same lengths is high, leading to a nonlinear rela-
tionship between fragment length and clone size [22,46].
Therefore, Gillet et al. used a calibration curve to statis-
tically correct the shear site data [22]. Later, Berry et al.
introduced a statistical approach, and further addressed
the difficulties of estimating clone size from shear site
data [46]. Their approach estimates the size of small
clones with little error, but estimates for larger clones
have greater error [46]. A parameter adopted from the
Gini coefficient [47,48] and termed the oligoclonality
index was used to describe the size and distribution of
HTLV-1 clones [22]. It has been demonstrated that the
oligoclonality index differs between malignant and non-
malignant HTLV-1 infections, and also a high PVL of
HTLV-1-associated myelopathy is due to cells harboring
large numbers of unique integration sites [22]. Further-
more, genome-wide integration site profiling of clinical
samples revealed that the abundance of a given clone
in vivo correlates with the features of the flanking host
genome [22,24]; although there was not a specific hot-
spot, HTLV-1 more frequently integrated in transcrip-
tionally active regions of the host genome [22,24]. These
findings further clarified the characteristics of HTLV-1
integration sites, and strongly suggested the importance
of HTLV-1 clonal expansion in vivo.
Here we introduce a method that overcomes many of the
limitations of currently available methods. Taking advantage
of next-generation sequencing (NGS) technology, nested-
splinkerette PCR, and a tag system, we designed a new
high-throughput method that enables specific isolation of
HTLV-1 integration sites and, most importantly, allows for
the quantification of clonality not only from the major
clones and high-PVL samples but also from low-abundance
clones (minor clones) and samples with low PVLs. More-
over, we conducted comprehensive internal validation ex-
periments to assess the effectiveness and accuracy of our
new methodology. A preliminary validation was conducted
by analyzing DNA samples from HTLV-1-infected individ-
uals with different PVLs and disease status. Subsequently,
an internal validation was performed that included an ap-
propriate control with known integration sites and clonality
patterns. We present our methodology, which illustrates
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quantification of clonal abundance.
Methods
Our clonality analysis method included two main as-
pects: (1) wet experiments, and (2) in silico analysis
(Additional file 1: Figure S1). A general explanation of
materials and methods is provided here, and detailed
protocols of the wet experiments are included in Additional
file 1: Notes. The in silico analysis is further described in
Results and discussion.
NGS data have been deposited in the Sequence Read
Archive of NCBI with access number of (SRP038906).
Wet experiments
Biological samples: specimens and cell lines
Specimens: In total five clinical samples were provided
by a biomaterial bank of HTLV-1 carriers, JSPFAD
[13,49]. The clinical samples were a part of those col-
lected with an informed consent as a collaborative pro-
ject of JSPFAD. The project was approved by the
Institute of Medical Sciences, the University of Tokyo
(IMSUT) Human Genome Research Ethics Committee.
Information about the disease status of samples was ob-
tained from JSPFAD database in which HTLV-1-infected
individuals were diagnosed based on the Shimoyama cri-
teria [50]. In brief, genomic DNA from PBMCs was iso-
lated using a QIAGEN Blood kit. PVLs were measured
by real-time PCR using the ABI PRISM 7000 Sequence
Detection System as described in [10].
Cell lines: An IL2-dependent TL-Om1 cell line [51]
was maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal calf serum (GIBCO), 1%
penicillin-streptomycin (GIBCO), and 10 ng/mL IL2
(R&D systems). The same conditions as those of patient
samples were used to extract DNA and measure PVL.
Illumina-specific library construction
We employed a library preparation protocol specifically
designed to isolate HTLV-1 integration sites. The final
products in the library that we generated contained all
the specific sequences necessary for the Illumina HiSeq
2000 platform (Additional file 1: Figure S2). These prod-
ucts included a 5′-flow cell binding sequence, a region
compatible with read-1 sequencing primer, 5-bp random
nucleotides, 5-bp known barcodes for multiplexing
samples, HTLV-1 long terminal repeat (LTR), human or
HTLV-1 genomic DNA, a region compatible with read-2
and read-3 sequencing primers, 8-bp random tags, and a
3′-flow cell binding sequence from 5′ to 3′, respectively
(Additional file 1: Figure S2B).
Incorporating the 5-bp random nucleotides downstream
of the region compatible with the read-1 sequencing primer
was critical and resulted in high-quality sequence data. Weused a library designed without the first 5-bp of random
nucleotides as input for the HiSeq 2000 sequencer in our
first samples (S-1, S-2, S-3, and S-4). Because all fragments
began with the same LTR sequence, clusters generated in
the flow cells could not be differentiated appropriately.
These samples resulted in low-quality sequence data (see
Additional file 1: Notes). Designing the first 5-bp randomly
resulted in high-quality sequence data for the remaining
samples because clusters were differentiated with no prob-
lem during the first five cycles of sequencing (data not
shown).
Our library construction pipeline comprised the fol-
lowing four steps (Additional file 1: Figure S2) (Additional
file 1: Notes):
(1) DNA isolation: DNA was extracted as described
above, and the concentration of extracted
DNA was measured with a NanoDrop 2000
spectrophotometer (Thermo Scientific). We
recommend using 10 μg of DNA as the starting
material. However, in practice there are some
rare clinical samples with limited DNA available.
In order to be able to handle those samples, the
method was also optimized for 5 μg and 2 μg of
starting DNA.
(2) Fragmentation: According to the protocol provided
in Supplementary Notes, the starting template DNA
was sheared by sonication. The resulting fragments
represented a size range of 300 to 700 bp as checked
by an Agilent 2100 Bioanalyzer and DNA 7500 kit
(Figure 1B).
(3) Pre-PCR manipulations: Four steps of end repair,
A-tailing, adaptor ligation, and size selection were
performed as described in Additional file 1: Notes.
(4) PCR: To amplify the junction between the genome
and the viral insert, we used nested-splinkerette
PCR (a variant of ligation-mediated PCR [52,53])
(Additional file 1: Figure S2). We confirmed that the
technique specifically amplifies HTLV-1 integration
sites; since there was no non-specific amplification
neither from human endogenous retroviruses nor
from an exogenous retrovirus such as HIV (see
Additional file 1: Table S1 and Additional file 2:
Figure S1).
Information on oligonucleotides, including adaptors
and primers, and the LTR and HTLV-1 reference se-
quences [54] are provided in Additional file 1: Table S1.
The final PCR products were sequenced using the HiSeq
2000 platform.
In silico analysis
Raw sequencing data were processed according to the
workflow described in the Results and discussion section.
Figure 1 Estimating clone size by ‘shear sites’. Also see Additional file 2: Figure S2 for a simple image from an integration site and its shear
sites. (A) Depicted is the complex population of uninfected cells (grey circles) together with infected clones (circles of different colors). A clone
is shown as a group of sister cells (circles of the same color) having the same integration site (IS). Different clones are distinguishable based
on differing integration sites, and thus the number of integration sites represents the number of infected clones. For example, the six different unique
integration sites refer to six unique clones. (B) Genomic DNA fragmented by sonication generates random shear sites (fragments of different length).
Fragment size, measured by an Agilent Bioanalyzer, ranged from 300 to 700 bp. This size range can theoretically provide approximately 400 variations. (C)
The size distribution of fragments decreased following amplification by integration-site-specific PCR. From the deep sequencing data, the original number
of starting fragments could be estimated by removing PCR duplicates and counting fragments with different lengths. For example, five different lengths of
PCR amplicons represent five infected sister cells. (D)We analyzed four samples, including (S-1: asymptomatic carrier (AC), (8% PVL)), (S-2: smoldering (SM),
(9% PVL)), (S-3: smoldering, (31% PVL)), and (S-4: acute, (33% PVL)). Using our method, the clone sizes were quantified by considering only shear sites. The
first major clone (the largest clone) of each sample was mapped to (chr 11-41829319 (+)), (chr 15: 59364370 (+)), (chr 4-563543 (-)), and (chr X - 83705328
(-)), respectively. The shear site variations of each major clone were 209, 119, 242, and 222, respectively. Different colors on the pie graphs indicate different
integration sites, and the size of each piece represents the clone size.
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the reverse read (100-bp) was termed Read-3 and an index
read (8-bp) was termed Read-2. In brief, analysis programs
were written in Perl language and run on a supercomputersystem provided by The University of Tokyo’s Human
Genome Center at The Institute of Medical Science [55].
The sequencing output was check for quality using the
FastQC tool [56]. The regions corresponding to the LTR
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against the reference sequences described in Additional
file 1: Table S1. Following isolation of the integration sites,
the flanking human sequences were mapped to the human
genome (hg19) (the UCSC genome browser [57]) by Bowtie
1.0.0 [58]. The final processed data included information
about shear sites (R1R3), tags (R1R2), and a combination of
tags and shear sites (R1R2R3). Fitting the data to the zero
truncated Poisson distribution for retrieving correlation
coefficients were done by the R-package ‘gamlss.tr’ [59].




We originally designed our method to overcome the limita-
tions of conventional techniques [31,34] and to make im-
provements in the only existing high-throughput method
[22]. In general, our method includes two main sets of wet
experiments and an in-silico analysis. We used genomic
DNA as the starting material to prepare an appropriate
library for Illumina sequencing. Subsequently, deep-
sequencing data were analyzed by a supercomputer.
The resulting information represents the clonality status of
each sample (Additional file 1: Figure S1).
There are complex populations of infected clones and
uninfected cells in a given HTLV-1 infected individual.
High-throughput clonality analysis requires monitoring
two main characteristics of clones: HTLV-1 integration
sites and the number of infected cells in each clone
(clone size). Each HTLV-1-infected cell naturally harbors
only a single integration site [23]. Therefore, the number
of detected unique integration sites corresponds to the
number of infected clones. Based on our analysis, which
is consistent with the data of Gillet et al. [22], employing
high-sensitivity deep sequencing allowed for the isola-
tion of a large number of unique integration sites (UISs),
including samples with low PVLs (Figure 1). We ana-
lyzed four samples from HTLV-1-infected individuals
with different PVLs, disease status, and expected clonal-
ity patterns. The samples include S-1: AC (8% PVL);
S-2: smoldering ATL (SM) (9% PVL); S-3: SM (31%
PVL); and S-4: acute ATL (33% PVL). Based on the final
optimized conditions, 1030, 39, 265, and 384 UISs were
isolated from each sample, respectively (Figure 1).
The most challenging aspect of our clonality analysis
was estimating the number of infected cells in each
clone. Although a necessary step in the analysis, PCR
introduces a bias in the frequency of starting DNA ma-
terial [40-45]. Because amplification causes significant
changes in the initial frequency of starting materials,
PCR products cannot be used directly to estimate the
amount of the starting DNA material. To overcome this
problem, we needed to manipulate DNA fragments tomake them unique prior to PCR amplification. Thus, if
each DNA fragment could be marked with a unique fea-
ture, it would then be possible to calculate its frequency
based on the frequency of that unique feature. When a sin-
gle unique stretch of DNA is amplified by PCR, the result-
ing product is a cluster of identical fragments termed PCR
duplicates. Therefore, to estimate the frequency of starting
DNA fragments, one should count the number of clusters
with unique features. The remaining technical question
then becomes how to mark the starting DNA prior to PCR
amplification. In the following section, we compare and
discuss two main strategies, namely (1) shear sites and (2) a
tag system, which enable DNA fragments to be uniquely
marked.
Estimating the size of clones by shear sites
The first strategy, described by Gillet et al., relies on
shearing DNA by sonication, resulting in fragments of
random length [22]. Sonication-derived shear sites were
thus used as a distinguishing feature to make fragments
unique prior to PCR. Clone sizes were then estimated by
statistical approaches [22,46].
To directly assess the effectiveness of the shear site
strategy, we analyzed the clonality of the aforementioned
clinical samples (S-1, S-2, S-3, and S-4). Genomic DNA
was cleaved by sonication with fragments in the 300- to
700-bp range, theoretically providing approximately 400
possible variations in fragment size (Figure 1A and B).
Following library construction, however, the final prod-
uct represented smaller size ranges, implying a relatively
limited number of variations (Figure 1C). Finally, the
number of PCR amplicons with unique shear sites was
retrieved from deep-sequencing data. See Additional
file 2: Figure S2 for a simple image from an integration
site and its shear sites. The data obtained from the shear
site experiments were not fitted to calibration curves or
statistical treatments, which were used by Gillet et al.
and Berry et al., respectively (See Additional file 1:
Notes) [22,46]. For clarity, only the information relating
to the major clone of each sample is provided in
Figure 1D. The shear-site variations of the major clone
were 209, 119, 242, and 222 for samples S-1 through S-
4, respectively. Even in the case of control samples with
100% PVLs, the shear sites did not provide more than
225 variations (see Validation of the methodology). How-
ever, it was expected that samples with differing PVLs
and disease status would harbor varying numbers of sis-
ter cells, at least in their major clones. Similar variations
of shear sites were observed in major clones of AC, SM,
and acute samples. These data suggest that, because the
number of sister cells in each clone exceeded the shear
site variations, the size of the clones was underestimated
(Figure 1). This is most problematic in the case of large
clones and leads to an underestimation of the clone size.
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We developed an alternate strategy to remove PCR bias
and to estimate starting DNA. We designed a tag system
in which 8-bp random nucleotides are incorporated at
the end of DNA fragments during adaptor ligation step.
Each tag acts as a molecular barcode, which gives each
DNA fragment a unique signature prior to PCR. Informa-
tion on the frequency of observed tags from the deep-
sequencing data can be used to remove the PCR duplicates
and thereby estimate the original clonal abundance in theFigure 2 Measuring clone size using the tag system. (A) The depiction
cells in large clones. As the number of the sister cells in a given clone incre
Prior to PCR, we incorporated 8-bp random tags into each DNA fragment to un
65,536 variations. The number of potential variations is expected to amply cove
remove PCR duplicates and to estimate the original number of starting fragmen
counted separately. For example, here five different combinations of tag
S-3, and S-4 were analyzed by the final optimal condition (Bowtie param
JT-10). Clone size was measured by tags only or by the combination of s
and 2675) and (269, 119, 1192, and 2038), respectively.starting sample. Owing to their random design, the tags
could theoretically provide approximately 65,536 variations.
This degree of potential variation is expected to provide a
unique tag for a large number of sister cells in each clone
(Figure 2).
We analyzed samples S-1, S-2, S-3, and S-4 to assess the
effectiveness of our tag system for estimating clone size.
The major clone of each sample showed tag variations of
393, 142, 1751, and 2675, respectively (Figure 2D). Similar
variations of tags and shear sites were observed in theabove shows that shear site variations are not able to cover all sister
ases, the probability of DNA shearing at the same site increases. (B)
iquely mark them. Random tags could theoretically provide approximately
r large numbers of the sister cells. (C) The tag information was used to
ts. If the fragments had the same shear sites but different tags, they were
s and shear sites represent five infected cells. (D) Samples: S-1, S-2,
eters: -v 3 - - best, and filtering condition: (merging approach)
hear sites and tags. The covered variations were (393,142, 1751,
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393) and (119 vs. 142)) (Figure 1D and Figure 2D). In all
four samples, those variations were also similar in the
minor clones of which the clone sizes did not exceed shear
sites variations (approximately <200 variations) (See
Additional file 1: Table S3 and Additional file 2: Table
S1 for information on the ten largest clones). However,
the variations covered by tags were significantly greater
than those of shear sites, especially for large clones like
those observed in the major clones of S-3 and S-4
((shear sites vs. tags): (242 vs. 1751) and (222 vs.
2675)). The variations covered by tags and combina-
tions were almost the same for all four samples ((tags
vs. combinations): (393 vs. 296), (142 vs. 119), (1751 vs.
1192), and (2675 vs. 2038)).
Upon comparison of the tag system data with the
shear site data, it was clear that both strategies yield es-
sentially the same results when the size of clones is small
enough to be covered by the number of shear site varia-
tions generated. However, the tag system provides a
much better estimation of clonality when the number of
sister cells in each clone exceeds shear site variations.
Therefore, clone size was underestimated when consid-
ering only shear sites in expanded clones like samples
S-3 and S-4. Given this, our tag system should be used
for samples with different clonality status to avoid
underestimation of the size of clones. See Additional file
2: Figure S3 for a simple comparison of shear site and
tag variations.
Validation of the methodology
Our newly developed method - the tag system and the
related data analysis - were successfully validated, intern-
ally. As mentioned above, the initial validation was done
by analyzing samples from different HTLV-1-infected in-
dividuals (Figures 1 and 2). Finally, we conducted a com-
prehensive internal validation by using an appropriate
control with known integration sites and clonality pat-
terns to provide direct evidence for the effectiveness of
our system in the clonality analysis. We designed a suit-
able control because there was not an appropriate con-
trol available. Using our system, we could evaluate the
method and confirm its accuracy, sensitivity, and repro-
ducibility. We selected two samples with the following
special conditions as starting materials for preparing the
control system.
Sample one (M): DNA from an acute ATL patient with
100% PVLs and a single integration site in the major
clone (Figure 3A). The integration site of this sample
was first checked with conventional splinkerette PCR,
which detected a single major integration site. Subse-
quently, deep-sequencing data (tags only and combina-
tions) showed that approximately 99% of the PVL
accounted for the major clone with an integration site atchromosome 12:94976747(-). A small numbers of clones
occupied approximately 1% of the PVL of this sample.
Those clones were only detected in the second trial sam-
ples for which the external PCR products were not di-
luted. Therefore, to simplify the overall analysis, we
removed those low-abundance clones (data not shown).
Sample two (T): DNA was isolated from a fresh cul-
ture of TL-Om1, which is a registered monoclonal ATL
cell line with 100% PVL and a single integration site at
chromosome 1:121251270(-) in each cell (Figure 3A).
Having prepared these two samples, they were sonicated
and mixed in proportions of 50:50 and 90:10 (Figure 3B).
These known proportions were thus expected to generate
specific patterns that could be verified with our subsequent
analysis. We conducted two independent sets of trials.
In the first trial, samples were named as ‘first trial con-
trol 1 ~ 4’ and abbreviated as 1st T-cnt-1 ~ 4. Various
amounts of DNA (μg) from samples M and T were
mixed to prepare the final expected clone sizes as shown
in Figure 3C. A 1-μL sample of a 10-fold dilution of ex-
ternal PCR product was used as the starting material for
nested PCR for this trial. The samples were run in separ-
ate lanes of HiSeq 2000.
We named the samples of the second trial as second
trial control-1 ~ 4 and abbreviated them as 2nd T-cnt-1
~ 4. DNA samples were mixed similarly to that for the
first trial except for sample four (Figure 3D). In contrast
to the first trial, we used 1 μL of the external PCR prod-
uct without any dilution as a starting material for the
nested PCR. These samples were multiplexed and run in
the same lane of HiSeq 2000. The purpose of the second
trial was to test both method reproducibility and the ef-
fect that the dilutions had on the results.
The samples of both the first and second trials were
analyzed under the same conditions, except where noted
above. For each control sample, expected patterns and
experimentally observed patterns were calculated for (a)
raw sequence reads, (b) shear sites, (c) only tags, and (d)
the combination of tags and shear sites (Figure 4). Figure 4
shows the data when the optimal conditions were consid-
ered. Additional file 1: Figure S3 includes most of the data
accumulated during optimization of the method.
Evaluating the accuracy of the clonality analyzed based
on shear sites vs. tags system
The ‘absolute error’, a technique used to evaluate system
accuracy [61], was used to assess our method. The ex-
perimental values were subtracted from expected values
(Figure 5A). Taking advantage of our control system (the
first and second trial samples), the clone size was calculated
by considering (a) sequencing reads without removing PCR
duplicates, (b) only shear sites, (c) only tags, and (d) the
combination of tags and shear sites (Figure 5B and C). The
absolute errors of raw sequence reads for the first trial
Figure 3 Preparing the control system. (A) The control system was designed by mixing sonicated genomic DNA (gDNA) of TL-Om1 with
that of an ATL patient in proportions of 50:50 and 90:10. TL-Om1 is a standard ATL cell line with 100% PVL and a known single integration site at
(chr1:121251270(-)). The patient sample was from an acute type of ATL with 100% PVL and a single integration site at (chr 12:94976747(-)). (B) The
expected clonality patterns: (50% vs. 50%), (90% vs. 10%), and (10% vs. 90%) were generated by mixing gDNA from an ATL sample with that from
TL-Om1. (C, D) Full details of the first trial’s and the second trial’s samples including: name of samples, total amount of DNA (μg), the amount of
DNA (μg) from TL-Om1 (T) vs. major clone (M), and expected clone size are provided. (E) Integration site position of TL-Om1 and the major clone
of ATL sample.
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the second trial samples were 44.66, 9.50, 6.88, and 60.24.
The magnitude of errors in the first trial was lower than
that of the second trial probably due to the dilution of the
external PCR products in the first trial. However because
dilution reduced the number of covered integration sites, itshould be done sparingly and with the purpose of the ex-
periments in mind. The errors when considering only shear
sites were 1.72, 34.33, 21.76, and 18.73 for the first trial and
0.47, 38.29, 36.72, and 40.47 for the second trial. Underesti-
mations caused by low shear site variation did not affect
the relative size of clones when the expected size of the
Figure 4 Validation of the tag system. For each control sample, both the expected and the experimentally observed patterns of raw
sequence reads, shear sites, and the combination of tags and shear sites are represented in the bar graphs. Abbreviations: Com.: Combinations, Exp.:
expected pattern, Seq.: raw sequencing data without removing PCR duplicates, Sh.: Shear sites, Tg.: Tags. (A) Clone size data of the first trial samples:
Data were obtained considering the final optimal conditions: (Bowtie parameters: -v 3 - - best, and filtering condition: (merging approach) JT-10). (B)
Clone size data of the second trial samples: Data were obtained considering the final optimal conditions: (Bowtie parameters: -v 3 - - best, and filtering
condition: (merging approach) JT-10-1%). See Additional file 1: Figure S4 for information on merging approach.
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http://genomemedicine.com/content/6/6/46clones was 50% vs. 50%. In this situation, shear sites
had the smallest error: 1.72 for 1st T-cnt-1 and 0.47 for
2nd T-cnt-1.
The errors were reduced in the data using the tag sys-
tem: 7.27, 5.23, 14.49, and 6.50 for the first trial, and
6.67, 7.07, 10.07, and 13.16 for the second trial. In thecase of the combination of tags and shear sites, errors
were: 6.98, 4.06, 0.21, and 1.31 for the first trial and 3.42,
10.51, 12.26, and 5.83 for the second trial. Interestingly,
the samples ‘tags only’ and ‘combinations’ showed similar
error levels. Based on these data, our system showed
lower absolute errors than when considering only shear
Figure 5 Evaluating the accuracy of the clonality analysis. (A) Absolute error is calculated by subtracting the expected values from the
experimentally observed values. (B, C) The accuracy of the method is evaluated by calculating the absolute error of the clone size estimation of
the control samples (see Figure 3). The y axis represents the percentage of absolute errors in different conditions including: (1) raw sequencing
reads without removing duplicated PCR, (2) only shear sites, (3) only tags, and (4) the combination of tags and shear sites. The absolute errors of
the final optimal condition: the first trial: (Bowtie parameters: -v 3 - - best, and filtering condition: (merging approach) JT-10), and the second trial:
(Bowtie parameters: -v 3 - - best, and filtering condition: (merging approach) JT-10-1%) are presented in this figure. Please refer to Additional file
1: Figure S6 for the absolute errors in all examined conditions. (B) The absolute errors of the first trial. (C) The absolute errors of the second trial.
See Additional file 1: Figure S4 for information on merging approach.
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http://genomemedicine.com/content/6/6/46sites (Figure 5) (Additional file 1: Figure S4). Owing to
differences in analyzed samples and system setups, we
could not directly compare our data with published
data [22,46]. Indirect evidence, however, provided by
shear site analysis of our own data illustrated that our
system has lower absolute errors than using the shear
site-based methodology.In-silico analysis
Processing, management, and analysis of the large
amount of data generated by deep sequencing require
special infrastructures and bioinformatics skills. We de-
signed a data analysis and interpretation pipeline specific
for HTLV-1 integration sites and clonality studies. The
workflow is provided in Figure 6. First, the raw data for
-Read-1 = 100-bp
Trim 5-bp random nucleotides
De-multiplex samples by 5-bp indices 
Trim 23-bp 
seq. from LTR-specific primer)
Blast 27 bp (left over seq. from LTR)
to LTR reference seq.
- +
remove Blast 45-bp to HTLV-1 reference seq
+
remove Collect the seq. & read IDs
Read 2 = 8-bp
Read-3 = 100-bp
Collect the read-3 with an ID corresponding  to read-1 ID
Trim and collect the first 41-/45-bp
(the same length as read 1)
Map to Hg19 by Bowtie






R1R3: Report IS positions 
based on the shear sites  
R1R2: Report IS positions 
based on tags
R1R2R3: Report based on 
combination of  shear sites and tags
41 bp: HTLV-1/Human27-bp LTR23-bp primer5-bpindex
5-bp
random




45 bp: HTLV-1/Human27-bp LTR23-bp primer5-bp
random
Read 1: Non-multiplexed samples
Figure 6 In-silico analysis work flow. (A) Illumina HiSeq 2000 platform outputs raw data of (Read-1 = 100 bp), (Read-3 = 100 bp), and (Read-2 =
8 bp). Data were analyzed according to this work flow after checking quality with the FastQC tool. In the case of Read-1, the first 5 bp were
trimmed, and the next 5 bp were used to de-multiplex indexed samples. The downstream 23 bp, which correspond to the LTR primer (F2), were
then removed. The next 27 bp were subjected to a blast search against the LTR reference sequence. For the blast search reads, the remaining
41/45 bp were subjected to a blast search against an HTLV-1 reference sequence. Reads were confirmed to be from HTLV-1 was removed, and
the sequences and IDs from the remaining reads which considered as human, were collected. Subsequently, Read-3 with IDs corresponding to
Read-1’s IDs were collected. The first 41/45 bp of Read-3 were trimmed and collected to have the same length as Read-1. The paired sequences
of Read-1 and Read-3 (same lengths) were mapped against hg19 by Bowtie with -v 3 - -best parameters. The 5′-mapped positions were considered to be
integration sites and the 3′-mapped positions as shear sites. Read-2 information was used to retrieve the clone size based on tags. Finally, the clone size
was computed by combining tag and shear site information. All the analyses were done by our own Perl scripts, which resulted in the following reports.
Report R1R3: the distribution of unique shear sites per integration site. Report R1R2: the distribution of unique tags per integration site. Report R1R2R3: the
distribution of unique tags and shear sites per integration site. (B, C) The structure of Read-1 for the non-multiplexed and multiplexed samples.
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http://genomemedicine.com/content/6/6/46high-throughput sequencing were checked for quality by
the FastQC tool. We then removed the first 5-bp ran-
dom nucleotides from read-1 and de-multiplexed those
samples that were run in the same lane of the HiSeq
2000 based on 5-bp of the known sequence (Figure 6
and Additional file 1: Figure S2). The downstream 23
nucleotides, which represented LTR-specific primers,
were also trimmed before further analysis. We then sep-
arated the remaining sequence of read one into two
different datasets: (1) LTR sequence and (2) HTLV-1 orhuman sequence. The former comprises the 27-bp se-
quence remaining from the LTR, whereas the latter is
composed of the 41-bp or 45-bp HTLV-1 or human se-
quence. In the case of multiplexed and non-multiplexed
samples, different lengths (that is, 41-bp and 45-bp)
were available for analysis. Both sets were subjected to
blast analysis against LTR and HTLV-1 reference se-
quences with one or two mismatches permitted, respect-
ively. Reads for which the sequence did not match
HTLV-1 were presumed to be human as long as their
Firouzi et al. Genome Medicine 2014, 6:46 Page 12 of 15
http://genomemedicine.com/content/6/6/4627-bp LTR sequences matched the LTR reference se-
quence. The resulting human reads were mapped to the
human genome (hg19) using Bowtie 1.0.0 [58]. We
employed various parameters of Bowtie and different
lengths of read three to obtain the optimal mapping
yield (Additional file 1: Table S2). These conditions were
achieved when a maximum of three mismatches were
permitted (-v parameter) and when the best alignment
regarding the number of mismatches was reported
(–best parameter). In addition, use of the same length of
read-1 as in read-3 allowed for better mapping results.
Mapping results are further discussed in Additional file
1: Notes.
The 5′-mapped regions were considered to be the po-
sitions of integration sites and reported as (chromosome:
position: (strand)) for example, (chr1:121251270: (-)). In
addition, 3′-mapped regions from read-3 were reported
as shear sites for each corresponding position. Informa-
tion on the tags, obtained from read-2, was used to de-
termine the size of clones as described in subsection:
Measuring the size of clones by the tag system. Final
outputs of our analysis - the three main reports: R1R3,
R1R2, and R1R2R3 - include information on shear sites,
tags, and a combination of tags and shear sites, respect-
ively (Figure 6).
Removing background noise
Data obtained from next-generation sequencers are not
error free [40,62-65]. There are many reports on the
error rate of Illumina sequencers [66,67]. Teemu Kivioja
et al. recently developed a system named unique mo-
lecular identifiers (UMIs) for quantifying mRNAs and
employed filtering criteria to remove false UMIs gener-
ated by sequencing errors [68]. In our study, consistent
with the data of Kivioja et al. [68], the sequencing errors
produced false tags with low frequencies. A filtering sys-
tem was required to remove those tags, which could
affect interpretation of our clonality data and reduce the
accuracy of the clone size measurement. To minimize
the effect of sequencing errors on data interpretation,
we tested different filtering conditions to remove back-
ground noise. Here, we report our proven filtering ap-
proach (Additional file 1: Figure S4).
Considering that tags are designed randomly, each tag
has an equal probability of being observed. Hence, the
distribution of tags should be fitted to the zero truncated
Poisson distribution [59,68]. Therefore, we test data fit
to the Poisson distribution to determine the efficacy of
each filtering condition. The distribution of tags for each
sample was measured by the R-package ‘gamlss.tr’ [59],
and the correlation coefficient was compared before and
after filtering (Additional file 1: Figure S6).
We used a filtering system, which we named the mer-
ging approach. The merging approach was conducted byclustering the tags and allowing only one mismatch so
that unique tags, differing only in one nucleotide (one-
mismatch permission), were merged. Subsequently, if
the frequency of observed tag reads (PCR duplicates)
was greater than 10, those unique tags were employed in
further analysis. Otherwise, they were considered as
artifacts. We referred to this filtering approach as ‘Join
Tag- remove10’ (JT-10) in the Figure legends. To facili-
tate understanding, these filtering conditions are illus-
trated in Additional file 1: Figure S4.
Final discussion
The advent of NGS technologies holds promise to reveal
the complex nature of neoplasms and to move past the
limitations of previous methods. Using different ap-
proaches starting from early cytogenetic analysis to later,
more elaborate studies with NGS technologies, the
clonal composition of different tumors has been ana-
lyzed [36-39]. Robust monitoring and tracking of clonal
dynamics using provirus integration sites allow for the
assessment of clonal composition of HTLV-1-infected
individuals from early infection to the final stage of
ATL development. To meet the technical requirements
for such type of analysis, we combined our expertise in
the field of HTLV-1 research and NGS analysis and
developed the high-throughput methodology described
herein.
Gillet et al. also recently introduced a high-throughput
method to extensively characterize HTLV-1 integration
site preferences and quantify clonality (further discussed
in Additional file 1: Notes) [22]. They statistically ana-
lyzed shear site data to estimate clone size. According to
their published data [22,46] and as well as our current
data, the limited variation in shear sites leads to an
underestimation of the size of large clones. Considering
that the incidence of large clones increases with disease
progression from the healthy AC state to the malignant
states of smoldering, chronic, or acute [22,46], an accurate
measurement of clone size - particularly large clones - is of
great clinical significance.
Our study is the first in which the size of large clones
was experimentally measured without using statistical
estimation. We have provided details of the method de-
sign, optimized experiment protocols, and in-silico data
processing workflow. To validate our methodology and
assess its accuracy, we analyzed eight control samples
with known integration sites and clone sizes, and four
clinical samples. We subjected the samples to deep se-
quencing so that they had enough read coverage for
each integration site and to ensure accurate measure-
ment of clone size (See Additional file 1: Notes). We
proved our methodology to be reliable for isolating large
numbers of integration sites and to be accurate for
quantifying clone size. Because the tag system could
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clone size, we were able to demonstrate that the mea-
surements are accurate.
Preliminary experiments on the clinical samples with
differing PVLs and disease status showed different
clonality patterns specific to AC and different ATL dis-
ease subtypes. S-1 was selected to represent still-healthy
but infected individuals (ACs), S-2 and S-3 to represent
indolent types of ATL, and S-4 to represent a typical ag-
gressive type of ATL. Despite similar PVLs, S-1 and S-2
could be distinguished based on clonality patterns (poly-
clonal vs. a shift towards oligoclonal): S-1: AC, 8% PVL,
and S-2: SM, 9% PVL. The clones of AC showed a uni-
form distribution pattern with no large difference in
clone size; clones of S-2, however, had non-uniform size.
S-2 and S-3 (S-3: SM, 31% PVL) are both smoldering
subtypes of ATL progression with differing PVLs (9% vs.
31%) and showed similar clonality patterns but a differ-
ent number of infected cells in each clone. S-3 and S-4
had similar PVL (S-4: acute, 33% PVL) but exhibited dif-
ferent clonality patterns: oligoclonal for S-3 (three or
four relatively large clones at the top surrounded with
other clones) vs. monoclonal for S-4 (a large major clone
surrounded with some small clones in the background).
After ranking the clones in order of descending size, we
noted that the size of the largest clone in the acute sam-
ple was 10 times that of the next clone (tags: (chr X:
83705328 (-)) = 2675 vs. (chr 14: 30655896 (+)) = 209).
Relative size of the major clone (chr X: 83705328 (-))
was also estimated by another method (PCR-southern)
(detailed information is provided in Additional file 2:
Figure S3 and Additional file 2: Supporting experi-
ments). Samples with distinct disease status (AC, SM,
and acute) manifested different clone sizes (Additional
file 1: Table S3 and Additional file 2: Table S1 include
the number of infected cells in the top 10 clones), but S-
1 vs. S-2 (0.60 vs. 0.67) and S-3 vs. S-4 (0.84 vs. 0.80)
could not be discriminated based on their oligoclonality
index (Additional file 1: Figure S7) (See Additional file 1:
Notes for further discussion). Therefore, it can be in-
ferred that, with an accurate measurement of clone size,
the application of this method will aid in the discrimin-
ation of ATL subtypes. These results suggest a possible
association between disease status, PVLs, and clonality
patterns. Hence, HTLV-1-infected individuals could be
classified in different groups based on their clonality pat-
terns, which could ultimately affect their choice of ther-
apy and estimation of prognosis.
Moreover, by interpreting information from previous
studies on HTLV-1 clonality [15,18-20,22,27,31,32,35]
and considering the data provided in our present paper, it
appears that ACs harbor a polyclonal population of HTLV-
1-infected cells, whereas ATL patients show monoclonal
patterns. Thus, changes in the clonality pattern and onsetof a clonal expansion of HTLV-1-infected cells seem to be
potentially applicable as a prognostic indicator of ATL on-
set. For these purposes, it is necessary to analyze appropri-
ate pools of samples from ACs and different subtypes of
ATL and to conduct a cohort study on the clonality pat-
terns of the sequential samples available over time.
Conclusions
We took advantage of next-generation sequencing tech-
nology, a tag system, and an in-silico analysis pipeline to
develop and internally validate a new high-throughput
methodology. The method was proved to accurately
measure the size of clones by analyzing control samples
with already known clone sizes and clinical samples. We
also discussed the novelty, significance, and applications
of our method, and compared it with the only existing
high-throughput method devised by Gillet et al. [22].
Employing our new methodology and the analysis of an
appropriate pool of samples provided by JSPFAD [13]
will be helpful not only for diagnosis and prediction but
also for elaborated understanding of the underlying
mechanism of ATL development. The methodology de-
scribed here could be adapted to investigate and quantify
other genome-integrating elements (such as proviruses,
transposons, and vectors in gene therapy). In addition,
the tag system can be used for quantifying DNA/RNA
fragments in RNA expression [68] or in metagenomics
for determining the size of bacterial populations.
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